Therapeutic Botulinum Toxin | Market Insights | Global | 2021
The COVID-19 pandemic will have a negative short-term effect on the global therapeutic BTX market. The deferral of nonurgent procedures, compounded with economic uncertainty across the globe will hinder procedure volumes and therefore impede market growth. Beyond the COVID-19 pandemic, the global therapeutic BTX market will grow strongly through 2029, with newly approved indications, the need for repeat BTX treatments, and a largely favorable reimbursement environment driving significant procedure volume and unit sales expansion.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for therapeutic BTX in the US, France, Germany, Italy, Spain, the UK, Japan and Australia across a 10-year period.
